Cargando…

Targeting KRAS in PDAC: A New Way to Cure It?

SIMPLE SUMMARY: Pancreatic cancer is one of the most intractable malignant tumors worldwide, and is known for its refractory and poor prognosis. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. KRAS is the most commonly mutated oncogene in PDAC. It has been consi...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Qianyu, Liu, Zuojia, Wang, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599866/ https://www.ncbi.nlm.nih.gov/pubmed/36291766 http://dx.doi.org/10.3390/cancers14204982

Ejemplares similares

Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future
por: Li, Chang, et al.
Publicado: (2022)

Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection
por: Dai, Manxiong, et al.
Publicado: (2022)

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
por: Jauset, Toni, et al.
Publicado: (2018)

Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
por: Reyes-Castellanos, Gabriela, et al.
Publicado: (2020)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
por: Digiacomo, Graziana, et al.
Publicado: (2021)

Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer
por: Guo, Xiaoyu, et al.
Publicado: (2018)

Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment
por: Speth, Cornelia, et al.
Publicado: (2022)

Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients
por: Guo, Shiwei, et al.
Publicado: (2020)

The Microbiome in PDAC—Vantage Point for Future Therapies?
por: Pfisterer, Nina, et al.
Publicado: (2022)

Combatting PDAC with two tumor-targeting small RNAs
por: Kasinski, Andrea L.
Publicado: (2019)

Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023)

Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
por: Hasbullah, Hidayati Husainy, et al.
Publicado: (2021)

PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia‐like features
por: Fukui, Katsuya, et al.
Publicado: (2022)

Scaling the immune incline in PDAC
por: Rojas, Luis A., et al.
Publicado: (2021)

Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?
por: Papadakos, Stavros P., et al.
Publicado: (2022)

SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells
por: Li, Siqin, et al.
Publicado: (2016)

Transverse Space Charge Effect During Bunch Compression in PDAC1 and PDAC2 Compressor Ring
por: Franchetti, Giuliano
Publicado: (2000)

Targeting the untargetable KRAS in cancer therapy
por: Liu, Pingyu, et al.
Publicado: (2019)

Autophagy is required for PDAC glutamine metabolism
por: Seo, Ju-Won, et al.
Publicado: (2016)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022)

Role of microbiota and microbiota‐derived short‐chain fatty acids in PDAC
por: Temel, Hülya Yılmaz, et al.
Publicado: (2022)

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC
por: Wang, Xiuchao, et al.
Publicado: (2020)

DA7R: A 7-Letter Zip Code to Target PDAC
por: Parrasia, Sofia, et al.
Publicado: (2023)

Immune-related somatic mutation genes are enriched in PDACs with diabetes
por: Wang, Kaixuan, et al.
Publicado: (2019)

Targeting KRAS in Pancreatic Cancer
por: Cowzer, Darren, et al.
Publicado: (2022)

Gepants — a long way to cure: a narrative review
por: Altamura, Claudia, et al.
Publicado: (2022)

Immunotherapy: A new target for cancer cure (Review)
por: Zhao, Fuqian, et al.
Publicado: (2023)

Five Ways to Cure a Cold
Publicado: (1891)

Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)
por: Chen, Hao, et al.
Publicado: (2023)

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
por: Kapszewicz, Monika, et al.
Publicado: (2021)

The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment
por: Papadakos, Stavros P., et al.
Publicado: (2023)

Disruption of Broad Epigenetic Domains in PDAC Cells by HAT Inhibitors
por: Gerrard, Diana L., et al.
Publicado: (2019)

Transgenic expression of Sag/Rbx2 E3 causes early stage tumor promotion, late stage cytogenesis and acinar loss in the Kras–PDAC model
por: Zhang, Qiang, et al.
Publicado: (2020)

SMAD4 Y353C promotes the progression of PDAC
por: Wang, Zusen, et al.
Publicado: (2019)

AHNAK2 is a potential prognostic biomarker in patients with PDAC
por: Lu, Di, et al.
Publicado: (2017)

CypA, a Gene Downstream of HIF-1α, Promotes the Development of PDAC
por: Zhang, Huan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qc8t8danp7pbqr8q07m9u5kipk